CAMZYOS is a non-invasive oral monotherapy that targets the underlying pathophysiology of obstructive HCM1, and therefore ensuring suitable patients are initiated on CAMZYOS as early as possible is paramount.
What factors do you need to consider to determine if your patient has obstructive HCM and may be suitable for CAMZYOS?
The CAMZYOS checklist
Adult (≥18 years old)1
Family history of one or more of the following:2,3
- Cardiomyopathy
- Sudden cardiac death
- Arrhythmias or unexplained syncope
- Other inherited cardiac conditions
Confirmed or suspected obstructive HCM1
- Peak LVOT obstruction gradient ≥50 mmHg at rest or with provocation4
One or more of the following potential signs and symptoms suggestive of NYHA class II–III HCM:5
- Peak LVOT obstruction gradient ≥50 mmHg at rest or with provocation
- Fatigue or tiredness
- Shortness of breath (also during activity)
- Chest pain (angina)
- Syncope
- Dizziness or light headedness
- Palpitations
- Arrhythmias
- Orthopnoea
- Pulmonary congestion
- Excessive sweating
Explore hypothetical patients who may be suitable for CAMZYOS –
do you see patients like these in your practice?
HCM, hypertrophic cardiomyopathy; ICC, Inherited Cardiac Conditions; LVOT, left ventricular outflow obstruction; NYHA, New York Heart Association.
References
- CAMZYOS (mavacamten) Summary of Product Characteristics.
- Alway T et al. Br Med Bull. 2024;150(1):11–22.
- Association for Inherited Cardiac Conditions. ICC Referral Pathway. Available at: https://www.theaicc.org/clinical-icc-pathways Date accessed: September 2025.
- Arbelo E et al. Eur Heart J. 2023;44(37):3503–3626.
- Zaiser E et al. J Patient Rep Outcomes. 2020;4(1):102.
- Konecny T, Somers VK. Chest. 2014;146(1):228–234.
- Maron BJ et al. J Am Coll Cardiol. 2002;39(2):301–307.
- O’Mahony C et al. Circ Arrhythm Electrophysiol. 2013;6(2):443–451.
- Ho CY et al. Circulation. 2018;138(14):1387–1398.